Canagliflozin, the second drug reviewed by the FDA in January 2013, also underwent a dedicated analysis on bone safety due to concerning findings in animal studies similar to those of dapagliflozin. Specific parameters that were evaluated included calcium, phosphorus, bone turnover markers and fracture rates. A phase II study found a 23-37% rise in the bone resorption marker CTX by week 3 which persisted until week 12. Likewise, an increase in PTH was observed by week 3, which returned toward baseline by week 6-12. At high doses, this study also demonstrated slight decreases in 25-hydroxyvitamin D as well as 1,25 hydroxyvitamin D.